These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 24351059

  • 1. Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study.
    Shirani A, Zhao Y, Karim ME, Petkau J, Gustafson P, Evans C, Kingwell E, van der Kop ML, Oger J, Tremlett H.
    Eur J Neurol; 2014 Jun; 21(6):835-44. PubMed ID: 24351059
    [Abstract] [Full Text] [Related]

  • 2. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
    Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Gustafson P, Petkau J, Tremlett H.
    JAMA; 2012 Jul 18; 308(3):247-56. PubMed ID: 22797642
    [Abstract] [Full Text] [Related]

  • 3. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
    Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD, Wynn DR, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA.
    Lancet Neurol; 2011 Apr 18; 10(4):338-48. PubMed ID: 21397567
    [Abstract] [Full Text] [Related]

  • 4. Interferon-beta and disability progression in relapsing-remitting multiple sclerosis.
    Drulovic J, Kostic J, Mesaros S, Dujmovic Basuroski I, Stojsavljevic N, Kisic-Tepavcevic D, Pekmezovic T.
    Clin Neurol Neurosurg; 2013 Dec 18; 115 Suppl 1():S65-9. PubMed ID: 24321159
    [Abstract] [Full Text] [Related]

  • 5. Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon.
    Bosca I, Coret F, Valero C, Pascual AM, Magraner MJ, Landete L, Casanova B.
    Mult Scler; 2008 Jun 18; 14(5):636-9. PubMed ID: 18566027
    [Abstract] [Full Text] [Related]

  • 6. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M, Sørensen PS, Andersson M, Celius EG, Jongen PJ, Elovaara I, Bartholomé E, Constantinescu CS, Beer K, Garde E, Sperling B.
    Lancet Neurol; 2010 Jul 18; 9(7):672-80. PubMed ID: 20542736
    [Abstract] [Full Text] [Related]

  • 7. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
    He A, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Girard M, Pucci E, Iuliano G, Alroughani R, Oreja-Guevara C, Fernandez-Bolaños R, Grand'Maison F, Sola P, Spitaleri D, Granella F, Terzi M, Lechner-Scott J, Van Pesch V, Hupperts R, Sánchez-Menoyo JL, Hodgkinson S, Rozsa C, Verheul F, Butzkueven H, Kalincik T, MSBase Study Group.
    JAMA Neurol; 2015 Apr 18; 72(4):405-13. PubMed ID: 25665031
    [Abstract] [Full Text] [Related]

  • 8. Brain atrophy as a non-response predictor to interferon-beta in relapsing-remitting multiple sclerosis.
    Rojas JI, Patrucco L, Miguez J, Besada C, Cristiano E.
    Neurol Res; 2014 Jul 18; 36(7):615-8. PubMed ID: 24620963
    [Abstract] [Full Text] [Related]

  • 9. New natural history of interferon-beta-treated relapsing multiple sclerosis.
    Trojano M, Pellegrini F, Fuiani A, Paolicelli D, Zipoli V, Zimatore GB, Di Monte E, Portaccio E, Lepore V, Livrea P, Amato MP.
    Ann Neurol; 2007 Apr 18; 61(4):300-6. PubMed ID: 17444502
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
    Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L, FREEDOMS study group.
    Lancet Neurol; 2012 May 18; 11(5):420-8. PubMed ID: 22494956
    [Abstract] [Full Text] [Related]

  • 15. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
    Lancet; 1998 Nov 07; 352(9139):1498-504. PubMed ID: 9820297
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
    Boz C, Oger J, Gibbs E, Grossberg SE, Neurologists of the UBC MS Clinic.
    Mult Scler; 2007 Nov 07; 13(9):1127-37. PubMed ID: 17967840
    [Abstract] [Full Text] [Related]

  • 20. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis.
    O'Rourke K, Walsh C, Antonelli G, Hutchinson M.
    Mult Scler; 2007 Apr 07; 13(3):336-42. PubMed ID: 17439902
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.